Glyco-engineered pentameric SARS-CoV-2 IgMs show superior activities compared to IgG1 orthologues https://www.biorxiv.org/content/10.1101/2022.12.22.521646v1?med=mas
Glyco-engineered pentameric SARS-CoV-2 IgMs show superior activities compared to IgG1 orthologues https://www.biorxiv.org/content/10.1101/2022.12.22.521646v1?med=mas